KRAS mutations are among the most common genetic alterations in human cancers. They are particularly prevalent in pancreatic cancer (approximately 90%), colorectal cancer (30-50%), and non-small cell lung cancer (15-30%). The frequency and impact of KRAS mutations can vary significantly among different types of cancer.
